



Aviragen Therapeutics, Inc.  
Investor Relations Department  
2500 Northwinds Parkway  
Suite 100  
Alpharetta, GA 30009  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AVIR**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 0.58                       |
| Trade Time:   | 4:00 PM ET<br>Jun 26, 2017 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | 0.53 - 0.59                |
| 52-Week Range | 0.43 - 2.00                |
| Volume        | 458,387                    |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapednavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplavovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- May 4, 2017*  
[Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results](#)
- Apr 4, 2017*  
[Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update](#)
- Feb 13, 2017*  
[Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapednavir](#)
- Feb 2, 2017*  
[Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results](#)
- Feb 1, 2017*  
[Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Sep 13, 2016*  
[Annual Report \(10-K\)](#)
- Sep 27, 2016*  
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Feb 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)